Navigation Links
Rubicon Genomics Selects Velesco to Manufacture its TransPLEX® RNA Amplification Kits for Clinical Diagnostic Use
Date:3/2/2012

ANN ARBOR, Mich., March 2, 2012 /PRNewswire/ -- Rubicon Genomics, Inc., a company developing and commercializing sample-specific pre-analytical processes to improve the capabilities and performance of DNA and RNA analytical platforms, today announced that it has selected Velesco Pharmaceutical Services to manufacture the TransPLEX® kits it will be supplying for use with Agendia's breast cancer diagnostics.  Velesco is a provider of analytical method development, drug formulation, stability testing and consulting services to biotech and pharmaceutical companies. It operates a 10,000 square foot cGMP manufacturing facility in Kalamazoo, Michigan.

"We are delighted to have found a highly qualified manufacturing partner located near our headquarters in Ann Arbor," commented James Koziarz, CEO of Rubicon. "Velesco's cGMP facility and quality processes are first-rate; its quality track record is impeccable and it has the formulation, fill and finishing expertise we need. Velesco provides us an immediate pathway to cGMP kits for diagnostic use and it has the capacity to rapidly expand cGMP production as sales of our diagnostic kits ramp up. We look forward to a mutually beneficial relationship as we grow our clinical diagnostics business."

Rubicon recently announced a clinical supply agreement with molecular diagnostics firm Agendia for the company's TransPLEX whole genome RNA amplification technology. Agendia is using Rubicon's kits to facilitate the analysis of FFPE (formalin-fixed, paraffin-embedded) patient samples for use with its Symphony™ breast cancer diagnostics. cGMP production of the TransPLEX kits is required as part of the FDA's 510(K) clearance process for the Symphony tests.

"We are pleased to be able to provide high quality cGMP manufacturing services to Rubicon as they expand into the clinical diagnostics arena," said Velesco Chief Operating Officer and co-founder Gerry Cox. "The availability of exceptional life science talent and infrastructure was a key reason we chose to grow our company in Michigan, and the addition of our neighbor Rubicon to our growing client list is another validation of that choice."

Velesco is a CMC contract research organization, founded and staffed by pharmaceutical scientists from Pfizer's former Michigan R&D campus. Velesco specializes in nimble, just-in-time cGMP drug product manufacturing, as well as traditional pharmaceutical cGMP manufacture.

Rubicon's TransPLEX RNA kits and GenomePLEX® DNA kits are members of its OmniPLEX® family of amplification technologies that are designed to deliver sufficient quantities of high quality nucleic acids to enable analyses of FFPE samples for biomedical research and clinical medicine. They use proprietary methods for advanced library synthesis and high-yield amplification to prepare samples for sensitive and accurate PCR, microarray and next-generation sequencing analysis. They have been used with thousands of clinical FFPE samples with exceptional consistency, superior performance and proven sensitivity. The OmniPLEX kits are fast, simple to use and amenable to automation. 

Terms of the agreement were not disclosed.

About Rubicon GenomicsRubicon Genomics, Inc. is a leader in the development and commercialization of sample-specific pre-analytical processes to improve the performance and capabilities of DNA and RNA analytical platforms for a variety of research and clinical testing applications. The company's core competency is the creation of more efficient molecular biology tools for genetic, epigenetic and expression analysis of difficult clinical samples to facilitate gene-based research, drug development, diagnostics and forensics. Privately held Rubicon is located in Ann Arbor, Michigan. More information can be found at www.rubicongenomics.com.

About Velesco Pharmaceutical ServicesVelesco was formed by former pharmaceutical R&D colleagues and focuses on supporting early stage drug development.  Velesco's founders, analytical chemists and drug formulation experts are pharmaceutical industry veterans working in the highest-quality facilities. Velesco delivers on time high quality products and services along with insightful consultation. More information can be found at www.velescopharma.com.

Contacts:Rubicon Genomics

MediaJames Koziarz

Barbara Lindheim or Jennifer AndersonChief Executive Officer

GendeLLindheim BioCom Partners jkoziarz@rubicongenomics.com

(212) 584-2276  

blindheim@biocompartners.com  

janderson@biocompartners.com


'/>"/>

SOURCE Rubicon Genomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
2. Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
3. Synthetic Genomics, Inc. and Integrated DNA Technologies, Inc. Sign Agreement to Manufacture, Market, and Commercialize Small Synthetic Gene Products Using SGI Technology
4. Smartphone Technology Meets Personalized Medicine in Everist Genomics CardioDefender Diagnostic System
5. AccuGenomics to Attend OneMedForum with Standardized Gene Expression Tests for Leukemia and Lung Cancer
6. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
7. Everist Genomics to Launch CardioDefender: Worlds Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians
8. Everist Genomics Announces Acquisition of Angiologix, Inc.
9. Synthetic Genomics Vaccines, Inc. Hires Vaccine Executive Sammy J. Farah as President
10. Cancer Game Changers: Genomics, Smarter Medicine, Care Coordination Comprise Medcos Advanced Oncology Solutions™
11. Everist Genomics Announces New Data on OncoDefender™- CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase ... The global anti-obesity drugs market is expected to ... the forecast period and CAGR of 38.7% in the second half ... a CAGR of 32.8% from 2016 to 2027. The market is ... $24,063 million in 2027. ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company ... January ECRM trade show to continue the marketing and distribution of its product, The ... for providing 400 percent better absorption than traditional vitamin C supplements. At the trade ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Lice Troopers, ... lice cases in families with school-aged children since the holiday season. , “It ... holidays with their families, sharing hugs and taking photos, which is the head-to-head gateway ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
(Date:1/20/2017)... California (PRWEB) , ... January 20, 2017 , ... "TransFlare ... to use inside of Final Cut Pro X," said Christina Austin - CEO of ... the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak ...
Breaking Medicine News(10 mins):